Parathyroid hormone in neonates

Alvaro Moreira, Melissa February, Cara Geary

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Aim: The goal of this study is to describe secondary hyperparathyroidism in extremely low birthweight (ELBW) neonates and their response to enteral calcium carbonate (CaCO3) supplementation. Methods: A retrospective case series was conducted on extremely low birth infants, <1000 g birthweight, who survived hospitalisation, had no major congenital anomalies and had all their care in our institution Results During this 6-year period, 231 ELBW infants survived hospitalisation at our institution. Of the 231 patients, parathyroid hormone (PTH) levels were performed in 66 of these patients (29%) and were elevated in 54 patients (82% of those tested). The timing of this testing was sporadic and was often performed after recognising osteopenia on radiography. Of the 54 patients with high PTH levels, 44 (81%) were treated with CaCO 3 and PTH levels were monitored while on therapy. The average duration of therapy was 41 ± 28 days, with 64% of PTH levels returning to normal before discharge. Conclusions: PTH is a major hormone responsible for bone resorption, and serum levels may be a useful marker in identifying ELBW neonates at risk for metabolic bone disease. ELBW neonates with secondary hyperparathyroidism may benefit from enteral supplementation with CaCO 3. Further studies are needed to better evaluate the incidence, timing and potential treatment of hyperparathyroidism in ELBW infants.

Original languageEnglish (US)
JournalJournal of Paediatrics and Child Health
Volume49
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Parathyroid Hormone
Newborn Infant
Secondary Hyperparathyroidism
Metabolic Bone Diseases
Small Intestine
Hospitalization
Calcium Carbonate
Hyperparathyroidism
Bone Resorption
Radiography
Therapeutics
Parturition
Hormones
Incidence
Serum

Keywords

  • calcium carbonate supplementation
  • extremely low birthweight infant
  • hyperparathyroidism
  • metabolic bone disease
  • osteopenia of prematurity

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Parathyroid hormone in neonates. / Moreira, Alvaro; February, Melissa; Geary, Cara.

In: Journal of Paediatrics and Child Health, Vol. 49, No. 1, 01.2013.

Research output: Contribution to journalArticle

Moreira, Alvaro ; February, Melissa ; Geary, Cara. / Parathyroid hormone in neonates. In: Journal of Paediatrics and Child Health. 2013 ; Vol. 49, No. 1.
@article{d8fc07455bcd453eab0334eb7d7d5e54,
title = "Parathyroid hormone in neonates",
abstract = "Aim: The goal of this study is to describe secondary hyperparathyroidism in extremely low birthweight (ELBW) neonates and their response to enteral calcium carbonate (CaCO3) supplementation. Methods: A retrospective case series was conducted on extremely low birth infants, <1000 g birthweight, who survived hospitalisation, had no major congenital anomalies and had all their care in our institution Results During this 6-year period, 231 ELBW infants survived hospitalisation at our institution. Of the 231 patients, parathyroid hormone (PTH) levels were performed in 66 of these patients (29{\%}) and were elevated in 54 patients (82{\%} of those tested). The timing of this testing was sporadic and was often performed after recognising osteopenia on radiography. Of the 54 patients with high PTH levels, 44 (81{\%}) were treated with CaCO 3 and PTH levels were monitored while on therapy. The average duration of therapy was 41 ± 28 days, with 64{\%} of PTH levels returning to normal before discharge. Conclusions: PTH is a major hormone responsible for bone resorption, and serum levels may be a useful marker in identifying ELBW neonates at risk for metabolic bone disease. ELBW neonates with secondary hyperparathyroidism may benefit from enteral supplementation with CaCO 3. Further studies are needed to better evaluate the incidence, timing and potential treatment of hyperparathyroidism in ELBW infants.",
keywords = "calcium carbonate supplementation, extremely low birthweight infant, hyperparathyroidism, metabolic bone disease, osteopenia of prematurity",
author = "Alvaro Moreira and Melissa February and Cara Geary",
year = "2013",
month = "1",
doi = "10.1111/jpc.12052",
language = "English (US)",
volume = "49",
journal = "Journal of Paediatrics and Child Health",
issn = "1034-4810",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Parathyroid hormone in neonates

AU - Moreira, Alvaro

AU - February, Melissa

AU - Geary, Cara

PY - 2013/1

Y1 - 2013/1

N2 - Aim: The goal of this study is to describe secondary hyperparathyroidism in extremely low birthweight (ELBW) neonates and their response to enteral calcium carbonate (CaCO3) supplementation. Methods: A retrospective case series was conducted on extremely low birth infants, <1000 g birthweight, who survived hospitalisation, had no major congenital anomalies and had all their care in our institution Results During this 6-year period, 231 ELBW infants survived hospitalisation at our institution. Of the 231 patients, parathyroid hormone (PTH) levels were performed in 66 of these patients (29%) and were elevated in 54 patients (82% of those tested). The timing of this testing was sporadic and was often performed after recognising osteopenia on radiography. Of the 54 patients with high PTH levels, 44 (81%) were treated with CaCO 3 and PTH levels were monitored while on therapy. The average duration of therapy was 41 ± 28 days, with 64% of PTH levels returning to normal before discharge. Conclusions: PTH is a major hormone responsible for bone resorption, and serum levels may be a useful marker in identifying ELBW neonates at risk for metabolic bone disease. ELBW neonates with secondary hyperparathyroidism may benefit from enteral supplementation with CaCO 3. Further studies are needed to better evaluate the incidence, timing and potential treatment of hyperparathyroidism in ELBW infants.

AB - Aim: The goal of this study is to describe secondary hyperparathyroidism in extremely low birthweight (ELBW) neonates and their response to enteral calcium carbonate (CaCO3) supplementation. Methods: A retrospective case series was conducted on extremely low birth infants, <1000 g birthweight, who survived hospitalisation, had no major congenital anomalies and had all their care in our institution Results During this 6-year period, 231 ELBW infants survived hospitalisation at our institution. Of the 231 patients, parathyroid hormone (PTH) levels were performed in 66 of these patients (29%) and were elevated in 54 patients (82% of those tested). The timing of this testing was sporadic and was often performed after recognising osteopenia on radiography. Of the 54 patients with high PTH levels, 44 (81%) were treated with CaCO 3 and PTH levels were monitored while on therapy. The average duration of therapy was 41 ± 28 days, with 64% of PTH levels returning to normal before discharge. Conclusions: PTH is a major hormone responsible for bone resorption, and serum levels may be a useful marker in identifying ELBW neonates at risk for metabolic bone disease. ELBW neonates with secondary hyperparathyroidism may benefit from enteral supplementation with CaCO 3. Further studies are needed to better evaluate the incidence, timing and potential treatment of hyperparathyroidism in ELBW infants.

KW - calcium carbonate supplementation

KW - extremely low birthweight infant

KW - hyperparathyroidism

KW - metabolic bone disease

KW - osteopenia of prematurity

UR - http://www.scopus.com/inward/record.url?scp=84872495305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872495305&partnerID=8YFLogxK

U2 - 10.1111/jpc.12052

DO - 10.1111/jpc.12052

M3 - Article

C2 - 23293851

AN - SCOPUS:84872495305

VL - 49

JO - Journal of Paediatrics and Child Health

JF - Journal of Paediatrics and Child Health

SN - 1034-4810

IS - 1

ER -